Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05413135 · ClinicalTrials.gov registry record · Phase 2
Study of ARO-APOC3 in Adults With Dyslipidemia
A Phase 2 study of Dyslipidemias, sponsored by Arrowhead Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 418
- Enrollment target
- 20
- Study locations
NCT05413135: Completed Phase 2 study of Dyslipidemias, sponsored by Arrowhead Pharmaceuticals.
NCT05413135 is a Phase 2 study of Dyslipidemias that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 418 participants, above the 218-participant average among 28 other Dyslipidemias trials with a reported enrollment target (92% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05413135, a Phase 2 study of Dyslipidemias, has completed, sponsored by Arrowhead Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 418 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility criteria had the option to be enrolled into this study. Eligible enrolled participants initially received open-label ARO-APOC3 every three or six months at the assigned dose level of the parent study until a final dose of 25 mg was selected, at which point all participants transitioned to the selected dosing regimen of 25 mg every 3 months.
Conditions Studied
Interventions
- DRUG ARO-APOC3
Study Locations (20)
Florida
- Clincal Research Site 4 - Boca Raton
- Clinical Research Site 5 - Fort Lauderdale
- Clinical Research Site 8 - Miami
- Clinical Research Site 6 - Miami
- Clinical Research Site 9 - Miami Springs
- Clinical Research Site 10 - Pembroke Pines
- Clinical Research Site 11 - Port Orange
California
- Clinical Research Site 1 - Beverly Hills
- Clinical Research Site 2 - Northridge
- Clinical Research Site 3 - Palm Springs
New York
- Clinical Research Site 17 - Long Island City
- Clinical Research Site 18 - New Windsor
- Clinical Research Site 19 - New York
Georgia
- Clinical Research Site 12 - Dunwoody
Minnesota
- Clinical Research Site 13 - Minneapolis
Mississippi
- Clinical Research Site 14 - Tupelo
Nebraska
- Clinical Research Site 15 - Omaha
Nevada
- Clinical Research Site 16 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2025-09-18 |
| Phase | Phase 2 |
What the finished NCT05413135 record still lists
NCT05413135 is an interventional study that assigns participants to a tested intervention. The registered 418 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 28 other Dyslipidemias trials with a reported enrollment target (92% higher).
The record links to 1 condition, with Dyslipidemias appearing as the primary indexed condition, and to 1 intervention - of which ARO-APOC3 is the first listed.
NCT05413135 names 20 study sites across 10 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT05413135 about?
NCT05413135 is a clinical study titled "Study of ARO-APOC3 in Adults With Dyslipidemia". This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility criteria had the option to be enrolled into this study. Eligible enrolled p...
What is the current status of trial NCT05413135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 418 participants. The study started on 2022-07-07. Estimated completion is 2025-09-18.
What conditions does trial NCT05413135 study?
This clinical trial studies the following conditions: Dyslipidemias.
What interventions are being tested in trial NCT05413135?
The interventions under investigation include: ARO-APOC3 (DRUG).
Who is sponsoring clinical trial NCT05413135?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05413135 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Minnesota, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05413135's enrollment target sits among peer trials
418 4th of 28 higher than 25 of 28 other Dyslipidemias trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemias trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Causal Mechanisms in Adolescent Arterial Stiffness
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
COMPLETED · Phase 2
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI